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Copy-Number Variations Measured by Single-Nucleotide–
Polymorphism Oligonucleotide Arrays in Patients with Mental
Retardation
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Michaela Nathrath, Dagmar Wahl, Babett Heye, Dieter Gla¨ser, Volkmar Liebscher,
Thomas Meitinger, and Tim M. Strom
Whole-genome analysis using high-density single-nucleotide–polymorphism oligonucleotide arrays allows identification
of microdeletions, microduplications, and uniparental disomies. We studied 67 children with unexplained mental re-
tardation with normal karyotypes, as assessed by G-banded chromosome analyses. Their DNAs were analyzed with
Affymetrix 100K arrays. We detected 11 copy-number variations that most likely are causative of mental retardation,
because they either arose de novo (9 cases) and/or overlapped with known microdeletions (2 cases). The eight deletions
and three duplications varied in size from 200 kb to 7.5 Mb. Of the 11 copy-number variations, 5 were flanked by low-
copy repeats. Two of those, on chromosomes 15q25.2 and Xp22.31, have not been described before and have a high
probability of being causative of new deletion and duplication syndromes, respectively. In one patient, we found a
deletion affecting only a single gene, MBD5, which codes for the methyl-CpG-binding domain protein 5. In addition to
the 67 children, we investigated 4 mentally retarded children with apparent balanced translocations and detected four
deletions at breakpoint regions ranging in size from 1.1 to 14 Mb.
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Mental retardation (MR) has a prevalence of ∼2%–3%.1
Whereas the frequencies of mild MR differ among studies,
most authors agree that severe MR, defined as an intelli-
gence quotient (IQ) of !50, has a prevalence of 0.3%–
0.4%.2 Aside from trisomy 21, which accounts for ∼5%–
15% of MR cases,2 chromosome abnormalities are detected
in not more than 5% of cases by cytogenetic analysis of
chromosomes prepared from peripheral-blood lympho-
cytes.3,4 The resolution of cytogenetic techniques is typi-
cally 5–10 Mb. Smaller rearrangements in the subtelo-
meric regions have been detected in ∼5% of affected
children by regional analysis using FISH or muliplex li-
gation-dependent probe amplification.5,6 It has further
been shown that another 10%–20% of rearrangements can
be found by array-based comparative genomic hybridi-
zation (array CGH).7–10 Recently, high-density SNP mi-
croarrays have been evaluated for this purpose.11,12 Special
efforts have been undertaken to analyze regions that are
flanked by segmental duplication, since these are known
to predispose to recurrent rearrangements in genomic dis-
orders.13 Array CGH and SNP microarrays have also re-
vealed the presence of several thousand copy-number var-
iations (CNVs) in the general population,14 complicating
the interpretation of the findings in disease cases.
Here, we used Affymetrix GeneChip Human Mapping
100K arrays (100K arrays) to analyze DNA from 67 chil-
dren with unexplained MR. Gains or losses that are likely
to be causative of the disease were present in 11 (16%) of
the children. We also show that the resolution of this array
is sufficient to detect single gene deletions in regions with
low gene content and that the determination of the break-
points is precise enough to amplify the junction fragments
after narrowing the breakpoint with few quantitative PCR
(qPCR) products, unless the breakpoints are flanked by
repetitive sequences or the rearrangement is complex.15
Material and Methods
Patients
The 67 children with unexplained MR were ascertained mainly
in a single human genetics practice (that of S.S. and B.K.). We
classified MR as mild or severe on the basis of clinical criteria and
the competence of adaptive behavior. If available, an IQ of !50
on a standardized IQ test was used to classify MR as severe. Ac-
cording to these criteria, 61 cases were classified as severe, and 3
cases as mild. Most of the children had additional but often mild
symptoms (table A1 in appendix A [online only]). Children with
brain malformations were excluded from the study. All children
had normal G-banded chromosomes (banding level 500–550). In
29 of the cases, cytogenetic analysis was performed in two dif-
ferent laboratories, with identical results. FISH with subtelomeric
probes and metabolic investigations were inconspicuous in 42
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and 11 children, respectively. DNA samples were available from
the parents of 44 children, which allowed us to investigate
whether CNVs originated de novo and to check which parental
allele was lost, in cases of de novo deletions. In addition to the
children with normal G-banded chromosomes, we analyzed DNA
from four mentally retarded children in whom de novo balanced
reciprocal translocations had been detected by cytogenetic anal-
ysis. DNA samples from 415 children referred for molecular di-
agnostics of the FMR1 gene but for whom no mutation was found
were used for sequence analysis of the MBD5 gene. The study was
approved by the Ethics Committee of the Medical Department
of the Technical University Munich.
Array CGH
Genomic DNA was isolated from peripheral-blood leukocytes by
use of a modified salting-out procedure.16 DNA concentrations
were measured with a NanoDrop spectrophotometer (ND-1000
V.3.1.2). The 100K arrays consist of two arrays, the Xba240 and
the Hind240 array, which together include 116,204 SNPs with an
average spacing of 23.6 kb. DNA was processed in accordance
with the manufacturer′s instructions. In brief, 250 ng of total
genomic DNA was digested with XbaI or HindIII and then was
ligated to adaptors. A generic primer that recognizes the adaptor
sequence was used to amplify the adaptor-ligated DNA fragments
in a GeneAmp PCR System 9700 (Applied Biosystems). After pu-
rification with the Macherey-Nagel NucleoFast 96 PCR Clean-Up
ultrafiltration technology, a total of 40 mg of PCR product was
fragmented and labeled with biotin. Hybridization was performed
in the Affymetrix GeneChip Hybridization Oven 640. Arrays were
washed and stained with the Affymetrix GeneChip Fluidics Sta-
tion 450 and were scanned with the Affymetrix GeneChip Scan-
ner 3000 7G. Image processing was performed with GCOS 1.4,
and genotypes were called with GTYPE 4.0 software by use of the
default call threshold of 0.25.
Data Analysis
To account for experimental variations, we hierarchically clus-
tered the euclidean distance matrix generated from the binary
logarithm of the sum of the median-normalized intensity values
of both alleles. The arrays were then ordered into groups with a
similar intensity profile. For each group, copy numbers were cal-
culated as follows. We first determined the raw intensity values
at each SNP locus by calculating separately the mean of the per-
fect-match probes for the A and B alleles. The raw intensity values
were then median normalized. The log2 ratio of the intensity
values were calculated separately for the three genotypes (AA, AB,
and BB) and the no-calls by dividing the normalized intensity
values of the test array by the median values of all arrays with
the same genotype for each SNP locus. One can show that the
noise is lower when genotype-specific intensity values are used
than when the sum of the intensity of both alleles for all ge-
notypes is used. To make intensity values from male and female
X chromosomes comparable, the mean dosage of the male SNPs
on the X chromosome was adjusted to the mean dosage of the
autosomal SNPs.
In many dosage plots, we observed that the mean dosage level
depended on the length of the restriction fragments. Thus, we
corrected for this dependence by using quadratic regression as
described elsewhere.17 This increased the signal-to-noise ratio
(SNR) further.
We used two measures for the assessment of data quality. First,
we calculated the SD and the median absolute deviation (MAD)
of the final log2 intensity ratios. Second, we calculated an SNR in
male DNA samples by substracting the median log2 intensity ratio
of the X-chromosomal SNPs from the median log2 ratio of the
autosomal SNPs. This difference was then divided by half the sum
of the MAD of the log2 intensity ratio of the autosomal and X-
chromosomal SNPs,
median[log (nonX)]median[log (X)]2 2SNRp .
{MAD [log (nonX)]MAD[log (X)]}/22 2
Note that the numerator measures the separation between the
log2 intensity levels of autosomal (“nonX”) and X-chromosomal
SNPs in males. Because of technological nonlinearities, this dif-
ference is !1. We found an average difference of 0.63 in 95 HindIII
arrays and of 0.70 in 98 XbaI arrays. The denominator estimates
the scale of the variation, putting equal emphasis on the auto-
somal and X-chromosomal SNPs. All characteristics are estimated
robustly, to safeguard against deviations from the standard nor-
mal model and against outliers.
The minimal number of consecutive lowly expressed SNPs that
significantly indicates a deletion was calculated with the
expression
5min{n:67# 10 # P(log CN2
n!0.5# sep ) ! 0.05}1copy,2copies
n 8{ }pmin n:F(0.5# SNR) ! 7.5# 10 ,
where is the median log2 intensity ratio of SNPs withsep1copy,2copies
1 copy or 2 copies, respectively; P denotes probabilities for CN,
the measured copy number of a SNP with real copy number 2
under a normal model; and F is the distribution function of the
standard normal distribution. The factor indicates the567# 10
Bonferroni correction for multiple testing.
We also implemented tools to select regions conspicuous for
gains and losses and to detect loss of parental alleles. To select
CNVs, we took into account the array-specific SD. The number
of consecutive SNPs had to be larger when the SD was higher. As
a minimum, we used the median of five consecutive SNPs to
define a CNV. Conspicuous regions were compared with known
CNVs, as provided by the Database of Genomic Variants and the
DECIPHER database. All analysis tools were implemented as R or
Perl scripts (available at Scripts Web site).
qPCR
We designed 1–3 amplicons for validation of each CNV (table A2
in appendix A [online only]). qPCR was performed on a 7900HT
real-time PCR system (Applied Biosystems) by use of SYBR Green
I for detection. Reaction mixtures contained 0.2 mM of each
primer and 10 ml of 2 # Power SYBR Green PCR Master Mix
(Applied Biosystems). Each assay included a no-template control,
two male and two female control DNAs, and the patient DNA at
a final concentration of 2.5 ng/ml in duplicate, in a total volume
of 20 ml. We used the same cycling conditions for all reactions:
initial step at 50C for 2 min, denaturation at 95C for 10 min,
then 40 cycles at 95C for 15 s, and a combined annealing and
extension at 58C for 60 s. To exclude the presence of unspecific
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products, a melting-curve analysis of the products was performed
after completion of the amplification. To control for differences
in DNA concentration, reaction efficiency, and threshold cycles
(Ct), the Ct values were normalized using the Ct value of a ref-
erence gene (BNC1) for each DNA sample. Analysis was performed
as relative quantification by use of the comparative Ct method.
Breakpoint Analysis
We used qPCR to narrow the interval of the deletion breakpoints
to 2–5 kb and generated junction fragments spanning the break-
points by long-range PCR (table A2). Junction fragments were
cloned into the pGEM-T vector (Promega) and were sequenced
using BigDye v3.1 cycle sequencing (Applied Biosystems).
Mutation Analysis
Dye-binding/high-resolution DNA melting analysis was used to
screen for single-nucleotide variations in MBD5. Unlabeled prim-
ers flanking each coding exon were designed with the ExonPrimer
software (table A2). Genomic DNA (∼10 ng) was subjected to PCR
amplification performed in 5 ml total volume containing 1#
Thermo-Start High Performance Buffer (ABgene), MgCl2 (1.25
mM), 100 mM of each deoxynucleotide triphosphate, 0.25 U of
Thermo-Start DNA polymerase (ABgene), primers (0.4 mM each),
and the dye LCGreen PLUS (Idaho Technology) at 1# final con-
centration. After PCR, the samples were heated to 94C for 30 s
and then were cooled to 20C before melting. Melting acquisition
was performed on a LightScanner HR I 384 instrument (Idaho
Technology) in accordance with the manufacturer′s standard pro-
cedures. Melting-curve data were analyzed with the standard soft-
ware provided by Idaho Technology. Abnormal melting profiles
were confirmed or excluded by sequencing of independent PCR
products.
X-Chromosome Inactivation Analysis
For the investigation of the X-chromosome pattern, we used the
trinucleotide repeat in the first exon of the androgen-receptor
gene.18 A total of 2 mg of DNA was digested with 20 units of the
methylation-sensitive restriction enzymes HhaI and HpaII (New
England Biolabs). After overnight digestion, an aliquot of 2 ml was
amplified by PCR by use of the FAM-labeled primer 5′-TCCAGAA-
TCTGTTCCAGAGCGTGC-3′ and the unlabeled primer 5′-GCTGT-
GAAGGTTGCTGTTCCTCAT-3′. The PCR products were separated
on an ABI Prism 3730 DNA sequencer and were analyzed with
the GeneMapper software (Applied Biosystems).
Results
Array Data Analysis
DNA from 67 patients with MR and normal G-banded
chromosomes and 4 patients with MR and a balanced
translocation diagnosis were analyzed with 100K arrays.
These arrays use a one-color technique; therefore, the nor-
malized intensity values of a test chip have to be compared
with one or more reference chips. We first assessed the
data quality by using the SD of the copy-number values
of all SNPs. Preliminary analysis showed that using the
arrays processed during the study instead of external ref-
erence arrays provided by the manufacturer resulted in
better data quality. We used hierarchical clustering to
group arrays with similar intensity profiles and observed
that the SNR could be increased when arrays with similar
intensity profiles were analyzed together. The HindIII and
XbaI arrays showed at least four and three groups, re-
spectively, with clearly distinctive intensity profiles (fig.
1). Differences in the intensity profiles are most likely
caused by DNA and experimental variations. Notably, ar-
rays processed in a single experiment tended to show sim-
ilar profiles. We eventually determined genotype-specific
log2 intensity ratios for each SNP locus within each group.
To increase the SNR further, we corrected for the depen-
dence of the log2 intensity ratio on the fragment length
by using quadratic regression. In total, we analyzed 169
array sets. The data quality was assessed by the SD and
the MAD of the log2 intensity ratio of all autosomal probes;
for the HindIII arrays, the mean SD was 0.19 and the mean
MAD was 0.16, and, for the XbaI arrays, the mean SD was
0.18 and the mean MAD was 0.16. These values are in
accordance with previously published reports.14,17
Different array types and platforms show different rates
of the increase and decrease for the log2 intensities because
of duplications and deletions, respectively. Thus, the MAD
or SD alone is not appropriate for the comparison of dif-
ferent array types and platforms. To render our results
comparable across different platforms, we estimated the
SNR by using the difference of the log2 intensity ratios of
the autosomal and the X-chromosomal SNPs of male sam-
ples. The HindIII arrays showed a mean SNR of 4.6, and
the XbaI arrays showed a mean SNR of 5.14. These values
mean that, on average, any six SNPs for HindIII arrays and
five consecutive SNPs for XbaI arrays indicate a deletion
at a 95% significance level over all 67 arrays. In our real
data, the individual arrays had different SDs, and the log2
intensity ratios were not normally distributed. We there-
fore adjusted the number of consecutive SNPs that define
a candidate region, depending on the SD, so that we ob-
tained at most eight CNVs per sample.
CNVs
By applying our rules for CNV detection, we obtained 27
candidate regions in 24 patients (table 1). All regions that
considerably overlapped with known CNVs provided by
the Database of Genomic Variants had previously been
excluded. The 27 candidate regions were evaluated by
qPCR. The 14 regions that were defined by 120 SNPs could
be confirmed by qPCR. Of the 13 regions defined by 5–
20 SNPs, 5 were determined to be false-positive findings.
In summary, we could confirm 22 CNVs (table 1). They
varied in size from 10 kb to 7.5 Mb and contained up to
49 genes. Genotype information revealed that four CNVs
originated on the paternal chromosome and two CNVs
on the maternal chromosome. From these 22 confirmed
CNVs, we further excluded five regions that were inherited
from one parent and six regions that did not contain
known coding regions or that could not be tested to de-
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Figure 1. Heat map of the median normalized intensity values of 169 HindIII arrays. The log2 intensity values of 1,000 SNPs are
displayed after hierarchical clustering. The sum of the intensity values of alleles A and B was used for this calculation. The columns
contain the different arrays; the rows contain the different SNPs. The banner across the top of the heat map shows a color code for
the four different time points at which the arrays were hybridized. Although the copy-number profile should be almost the same for
each chip, it shows at least four clearly separated groups.
termine whether they occurred de novo, because we did
not have parental DNA available.
We finally considered 11 CNVs—8 deletions and 3 du-
plications—to be causative of MR by criteria as follows
(fig. 2 and table 2). Eight of the rearrangements were as-
sumed to be causative because they occurred de novo. Two
rearrangements, in 8p23.1 and 17p11.2, were assumed to
be causative because they overlapped with known deletion
or duplication syndromes (e.g., 17p11.2 duplication syn-
drome [MIM 610883]), although they could not be proved
to have occurred de novo, because of missing paternal
DNA. At last, a maternally inherited 1.4-Mb duplication
in Xp22.31, including the STS gene, in a male patient was
thought to be causative because deletions of this region
are known to cause MR and because the chromosome car-
rying the duplication was nonrandomly inactivated in the
mother.
In addition, we investigated DNA of four mentally re-
tarded children with de novo translocations—three ter-
minal and one interstitial translocation—containing a
total of eight breakpoints. According to GTG-banding
analysis, they appeared to be balanced. By microarray
analysis, we detected deletions at two of the six break-
points in the terminal translocations and at two of the
breakpoints in the interstitial translocation containing 3–
63 genes (table 3).
CNVs Flanked by Low-Copy Repeats
Of the 11 validated CNVs, 5 were flanked by low-copy
repeats (LCRs). The first one was a 3.9-Mb deletion in
8p23.1, indicated by 177 SNPs in a child (patient identi-
fication [ID] 29922) with mild MR. The mother carried
two copies, and the maternal genotypes in the deleted
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Figure 2. Genomic profiles showing the log2 intensity ratios of CNVs and of the surrounding genomic regions detected in patients
with MR. The length of the CNVs is indicated on the X-axis. log2 Intensity ratios are calculated as described in the “Material and
Methods” section. Displayed are the log2 intensity ratios after median smoothing with a window of 9. The dosage values of homozygous
and heterozygous SNPs are depicted in black and gray, respectively. The gray horizontal lines are drawn at log2(0.75) and log2(1.25).
region are consistent with the boy carrying one of the
maternal alleles. Thus, it is most likely that the deletion
occurred on the paternal chromosome, although we did
not have paternal DNA available for investigation. The
deletion overlapped with the known 8p23.1 deletion syn-
drome and included the GATA4 gene, as confirmed by
qPCR.19 The syndromic features of our patient included
microcephaly, hypospadia, and an atrial septum defect de-
scribed to be attributable to haploinsufficiency of GATA4.20
The child did not present with facial dysmorphisms, di-
aphragmatic hernia, or epilepsy.
The second CNV flanked by LCRs was a duplication of
3.2 Mb in 17p11.2, indicated by 29 SNPs in a boy (ID
27737) with mild MR. His mother carried two copies. DNA
from the father was not available. As estimated by the
dosage values, the duplication coincides with the com-
mon 3.7-Mb interstitial duplication of the 17p11.2 du-
plication syndrome, a region that harbors deletions in
Smith-Magenis syndrome (MIM 182290).21,22 The patient
we investigated had normal birth weight and length, but
feeding was poor, and he failed to thrive postnatally. He
had a hypospadia grade I. At age 10 mo, his length was
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Table 2. Deletions and Duplications
Patient
ID
Gain
or
Loss Chromosome
SNP
Region
Length
(Mb)
No.
of
SNPs
No. of
Genes
Segmental
Duplications
LOHa
No. of
qPCRs
Confirmation
by Second
HybridizationStart End Paternal Maternal
27384 Loss 1q31.1-31.3 rs10494585 rs10494695 7.5 464 17 No 48 0 1 Yes
29922 Loss 8p23.1 rs2945251 rs2466115 3.9 177 34 Yes NA 0 3 No
30437 Loss 2p25.3-25.1 rs2313466 rs1964092 3.8 193 4 No 0 18 1 No
27737 Gain 17p11.2 rs4073940 rs1373147 3.2 29 49 Yes NA … 3 Yes
30375 Loss 3p25.3-25.2 rs10510400 rs10510422 2.7 98 39 No 8 0 3 No
28735 Loss 12p13.33 rs953385 rs2283285 2.0 62 18 No 4 0 3 No
28430 Loss 15q25.2 rs17158372 rs10520569 1.4 27 11 Yes 0 2 3 Yes
29836 Gain Xp22.31 rs719632 rs10521669 1.4 31 5 Yes … … 3 Yes
30428 Loss 17q21.31 rs436667 rs1918798 0.5 38 7 Yes 26 0 1 Yes
28701 Gain 13q12.11 rs9315234 rs4570685 0.5 23 5 No … … 3 Yes
29195 Loss 2q23.1 rs2890919 rs10497034 0.2 13 1 No 0 0 2 Yes
NOTE.—NA p not available.
a The number of SNPs for which a paternal or maternal allele is missing. LOH p loss of heterozygosity.
in the 10th percentile, his head circumference was !3rd
percentile, and he was found to have hypotonia. Facial
features, such as telecanthus, triangular face, and broad
forehead, were in accordance with the findings recently
described in other children who were given a diagnosis of
Potocki-Lupski syndrome (fig. 3A).22 Later, the mother re-
ported that the child started speaking single words only
at age 27 mo.
The third CNV flanked by LCRs was a 500-kb deletion
in 17q21.3 in a girl (ID 30428) with moderate MR. The
deletion encompasses a known inversion polymorphism.23
We used the genotype information from 38 SNPs within
the deleted region to define the haplotypes in the girl and
her parents. The father was homozygous for the H2 hap-
lotype, and the mother was homozygous for the H1 hap-
lotype. The deletion occurred on one of the paternal H2
haplotypes. Deletions of the same region have recently
been found in 10 other patients and have defined a new
microdeletion syndrome.13,24,25 The deletions reported
therein also occurred on the H2 haplotype and may be
facilitated by the direct orientation of the repeats on this
haplotype.
The fourth CNV flanked by LCRs was a 1.4-Mb deletion
on chromosome 15q25.2, which comprises ∼11 genes, in
a patient (ID 28430) with mild MR. Both parents carried
two copies of the region. The deletion was indicated by
the dosage values of 27 SNPs. Two informative SNPs
showed that the maternal allele was deleted. The patient
was affected by intrauterine growth retardation. She was
born in the 38th wk of gestation, with a weight of 1,950
g and a length of 42 cm. She had only very slight dys-
morphic signs. The main symptoms were psychomotor
retardation, polysplenia, and a hypoproliferative, macro-
cytic anemia that developed in the 1st year of life and that
required blood transfusions until she was age 4 years. Be-
cause of short stature and anemia, the diagnosis Diamond-
Blackfan anemia (MIM 105650) was considered. At age 11
years, she was referred to the emergency ward with bleed-
ing from esophageal varices. Ultrasound sonography re-
vealed a severe portal vein stenosis, although liver struc-
ture was normal.
The fifth CNV flanked by LCRs was a 1.4-Mb duplication
in Xp22.31 in a boy (ID 29836) with severe MR. The du-
plication was located between the VCX3A and VCX2 genes
and was indicated by 18 SNPs (fig. 4A). qPCR revealed a
single dose for amplicons ∼6 kb distal to VCX3A and 3 kb
proximal to VCX2, whereas amplicons 3 kb proximal to
VCX3A and 5 kb distal to VCX2 showed a double dose.
Therefore, VCX3A or VCX2 is duplicated or an addition-
al fusion product of both genes was generated, depend-
ing on where the recombination occurred. In addition,
all genes between VCX3A and VCX2 are duplicated
(HDHD1A, STS, VCX, and PNPLA4). Investigations of the
parental DNAs showed that the father had a single copy
of this region, whereas the healthy mother had three cop-
ies and therefore is a carrier of the duplication. Studies of
the X-inactivation pattern in peripheral-blood DNA of the
mother showed a nonrandom X-inactivation, with the
chromosome carrying the duplication being inactivated.
We therefore conclude that the duplication is most likely
causative of the MR in her son. He had normal motor
development but showed, in addition to MR, speech and
language deficits. At age 9 years, he used only 2-word sen-
tences. He developed postnatal microcephaly, with a head
circumference of 50 cm (3rd percentile) at age 9 years. A
recent report describes additional patients with MR car-
rying duplications of this region.26 The same region con-
tains deletions in 80%–90% of patients with X-linked ich-
thyosis (MIM 308100) caused by deficiency of the steroid
sulfatase enzyme, encoded by the STS gene.27 Most pa-
tients with deletions are affected only by ichthyosis, but
a few also display MR, although the size of the deletion
is often very similar to that of the deletion breakpoints
situated near the directly orientated genes VCX3A (VCXA)
and VCX2 (VCXB), which are embedded in an LCR of ∼9
kb. Data from two studies suggested that, depending on
whether VCX-proximal or VCX-distal homologous se-
quences are used for recombination, VCX3A is deleted and
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Figure 3. Facial features of patients. A, Patient 27737, with a
common 17p11.2 duplication, at age 10 mo, showing a telecan-
thus, triangular face, and broad forehead. B, Patient 29195, with
an MBD5 deletion, at age 15 mo, showing a normal facies without
dysmorphic features.
Table 3. Reciprocal Translocations
Patient ID, GTG Banding,a
and Chromosomeb
SNP
Region
Length
(Mb)
No.
of
SNPs
No.
of
GenesStart End
31922, 46,XY,t(12;13)(q22;q32):
13q33.2-33.3 rs2149144 rs9301245 1.8 146 3
28526, 46,XY,t(1;10)(p13.1;p13):
10p14 rs2259442 rs1243963 1.1 57 8
28181, 46,XY,t(4;6)(q28.3q31.1;q23.1q22.2):
4q28.3-31.1 rs10519357 rs6841039 3.9 186 6
6q16.1-21 rs9320518 rs6568702 14.3 625 63
a GTG banding (with 500–550 bands) contains results of karyotyping.
b Chromosome contains results of microarray experiment.
VCX2 is retained, or vice versa.28,29 MR seems to be asso-
ciated with the deletion of VCX3A,29 although the data
are not unequivocal, because patients with Xp;Yq trans-
locations leading to a deletion of VCX3A have been re-
ported to have normal intelligence.
CNVs Not Flanked by LCRs
In six patients, de novo CNVs could be identified, with a
size between 200 kb and 7.5 Mb. The child (ID 27384)
with the largest deletion (7.5 Mb) has psychomotor re-
tardation but did not have additional symptoms besides
slight dysmorphic facial features. The most prominent
syndromic features in these six patients included hydro-
cephalus and cleft palate (in patient 28701), microcephaly
and adipositas (in patient 30437), and an ostium secun-
dum defect (in patient 30375). The 2.7-Mb deletion in the
last boy (ID 30437) overlapped with the proximal part of
the 3p syndrome, which has been described to cause atrio-
ventricular septal defects in most of the affected individ-
uals.30 The 3.8-Mb deletion on 2p25.1-25.3 contained only
four genes, including SOX11. This gene is expressed tran-
siently during embryonic development in many tissues
and causes severe defects in several organ systems in ho-
mozygous Sox11-deficient mice, leading to death shortly
after birth.31
The smallest CNV suggestive of being causative of the
clinical phenotype observed is a 200-kb deletion on chro-
mosome 2q23.1 in a boy (ID 29195) with severe MR. The
deletion was indicated by 13 SNPs, which affected the first
7 of 10 exons of the methyl-CpG–binding domain protein
5 gene (MBD5) (fig. 4B). The deletion region was present
in the parental DNA but provided no information with
regard to the origin of the deletion. Sequencing of the
coding region of the remaining allele did not show any
deviation from the reference sequence (GenBank acces-
sion number NM_018328). The junction fragment was
amplified and sequenced after the breakpoints were nar-
rowed by qPCR (GenBank accession number EF504248).
The proximal breakpoint lies within an LTR/ERVL repeat
(MLT2B5), and the distal breakpoint lies within single-
copy sequence in intron 7 of the MBD5 gene. ESTs sug-
gested that the GenBank entry for MBD5 is 5′ incomplete.
We extended the mRNA by five noncoding exons, using
5′ rapid amplification of cDNA ends (RACE) and RT-PCR
(GenBank accession number EF542797). The boy had a
sandal gap between the first and second toe but no facial
dysmorphic features (fig. 3B). In addition to MR, motor
development was slightly retarded. At age 8 mo, he had
febrile seizures. First seizures without fever started at age
16 mo and proved to be drug resistant. The boy is hy-
poactive, and social interactions are very limited. To pro-
vide further evidence of the pathogenicity, we screened
415 DNAs from children with MR. We found four missense
variants that were not present in ∼660 controls (table 4).
We did not have parental DNAs available to check whether
these variants occurred de novo.
MBD5 was originally identified because of sequence ho-
mologies to MBD1–MBD4 and MECP2, which is mutated
in Rett syndrome.32 It also contains a PWWP motif, which
has been shown to bind to DNA and is found in proteins
often containing other chromatin-association domains.33
Discussion
Hybridization using synthetic oligonucleotide arrays of-
fers great promise for the detection of submicroscopic
deletions and duplications. As the technology evolves,
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Figure 4. Schematic representation of the regions affected in patients 29836 and 29195. A, Duplication in Xp22.31 in patient 29836.
Genes are indicated by white boxes. The arrows denote the direction of transcription. The primers used for qPCR are shown above the
genomic representation as numbered black bars. Primers 9060 and 9821 showed a single dosage; primers 9822 and 9820, a double
dosage. The nonallelic homologous recombination must have occurred within the homologous regions flanked by primers 9060 and
9820 and primers 9822 and 9821. B, Deletion of part of the MBD5 gene in patient 29195. Exons are indicated by numbered black boxes
(untranslated sequence) or gray boxes (translated sequence). The extent of the deletion is shown by a black bar below the gene scheme.
Exons 1A–1E of MBD5 denote the 5′ untranslated exons established in this study.
driven mainly by the need for dense SNP arrays in ge-
nomewide association studies, the resolution to detect rel-
atively small deletions and duplications with strong effects
on rare phenotypes will improve. We used arrays that
cover the entire genome, with 100,000 SNPs, to test them
against 71 patients with MR. Samples from all 71 patients
had previously been subjected to cytogenetic analysis, be-
cause they had slight or overt symptoms characteristic of
chromosomal abnormalities.
Our study led to the identification of 11 deletions or
duplications that were interpreted to be causative, because
they could be shown to have occurred de novo or because
they corresponded to established disease-associated indel
mutations. Our detection rate of 16% is in the same range
as that of earlier studies that used 100K arrays12 or whole-
genome tiling-path resolution array CGH.7 The patient (ID
29922) with 8p23.1 deletion syndrome and the patient
(ID 27737) with 17p11.2 duplication syndrome raise the
question of why the clinical picture in these patients did
not lead to a specific diagnosis and testing. In both cases,
the differential diagnosis did include the mentioned syn-
dromes, but its features were by no means unequivocal.
In the case of the 17q21.3 deletion, the genotype-phe-
notype connection was established only during the course
of this study.13,24,25
We identified two CNVs, in 15q25.2 and Xp22.31, with
a high probability of being causative of new deletion and
duplication syndromes. They were flanked by LCRs, which
make it likely that other cases exist, both deletions and
duplications. Whereas no other cases have been described
so far for 15q25.2, duplications in Xp22.31, which are
characterized by MR in combination with autistic behav-
ior, seem to be more frequent.26
The smallest CNV detected and concluded to be caus-
ative is a deletion of a single gene, MBD5 (in patient
29195). The deletion measured 200 kb in size. It was de-
tected by 13 consecutive SNPs and deleted one noncoding
and seven coding exons of the gene, which codes for the
methyl-CpG–binding domain protein 5. Two previous re-
ports and a DECIPHER entry (about patient 1079) have
described contiguous gene deletions that also involve the
MBD5 gene7,34 (J. Veltman, personal communication). The
clinical features of our case patient and two of the pre-
viously described patients include epileptic seizures. A mu-
tation screen involving 415 DNAs of children with un-
explained MR revealed four missense variants not present
in 660 controls, but no deletions or nonsense mutations
were found. We could not check whether the missense
variants occurred de novo because we did not have pa-
rental DNA available. Thus, a confirmation that the MBD5
mutations are pathogenic awaits the screening of a panel
enriched for epileptic seizures for which parental DNA is
available.
The CNVs suggest that the genes involved cause the
related pathology by dosage differences. The most likely
group of genes to be considered for such a mechanism is
transcription factors.35 With the exception of the MBD5
deletion, the Xp22.31 duplication, and the 17q21.31 de-
letion, all regions contained at least one gene involved in
the transcription process. From the 189 genes contained
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Table 4. Variations in MBD5
Variation Type
and Sequence
Change
Protein
Change Patient ID(s)
Exon/
Intron
No. of Control Individuals
with Genotype
11 12 22
Nonsynonymous:
c.431CrT p.T144I A12 4 CC: 660 CT: 0 TT: 0
c.1368GrT p.S456K A6 and B135 4 GG: 663 GT: 1 TT: 0
c.1382GrA p.R461H A47 and B217 4 GG: 649 GA: 0 AA: 0
c.1962CrA p.D654E C231 4 CC: 655 CA: 0 AA: 0
c.1963GrA p.A655T 30224a 4 GG: 653 GA: 0 AA: 0
c.2030GrA p.S677N B134, C264, and C281 4 GG: 662 GA: 3 AA: 0
c.2569GrA p.A857T 31833a 5 GG: 670 GA: 0 AA: 0
c.3143CrT p.T1048I C260 7 CC: 640 CT: 0 TT: 0
Synonymous:
c.1638CrT p.A546A A109 and B139 4 CC: 658 CT: 3 TT: 0
c.2286CrT p.H762H B225 4 CC: 338 CT: 0 TT: 0
c.3279CrT p.V1094V A53 7 TT: 648 CT: 0 CC: 0
a One of the parents carries the same mutation.
in the reported deletions and duplications, 129 have a
Gene Ontology annotation, and 16 (12%) of those 129
are annotated as transcription factors.
We showed that 100K arrays allow the detection of
CNVs with a size between 10 kb and 7.5 Mb, a range that
is not reliably accessible by microscopic cytogenetic tech-
niques. The quality of the intensity data obtained from
the arrays was variable and depended on the experimental
circumstances, restrictions that must be accounted for in
the analysis procedure. The detection of CNVs by at least
20 neighboring SNPs was found to be reliable, whereas the
detection of CNVs by 5–20 neighboring SNPs had a false-
positive rate of 30%. The resolution might improve with
new protocols and new generations of arrays that reduce
the experimental error and provide a better SNR. The in-
terpretation of the results in children with MR or other
diseases is complicated by the presence of thousands of
CNVs within the normal population, especially when
their size is small. One usually applies the criterion that
a CNV has to have occurred de novo for it to be likely
pathogenic. However, the frequency of de novo deletions
and duplications in newborns has been estimated to be 1
in 8 and 1 in 50, respectively, and it is obvious that not
all of them can be assumed to be pathogenic.36 On the
other hand, de novo CNVs may be pathogenic. They may
provide a risk that becomes manifest because of sequence
variants in the other allele or the genetic background. Da-
tabases that collect information about CNVs in healthy
individuals and individuals with diseases will become in-
dispensable for their risk estimation. This will become
even more important when improved array designs allow
detection of intragenic deletions and duplications.
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